1 completed, 1 recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Multiple Myeloma, Plasma Cell Leukemia: new trials by email Literature Review of Multiple Myeloma, Plasma Cell Leukemia trials Research Report on Multiple Myeloma, Plasma Cell Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia Autologous hematopoietic stem cell transplantation, BCMA CAR-T, GPRC5D/CD3 BiTEs - Multiple Myeloma, Plasma Cell Leukemia | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2025-08-10 | 2025-08-06 |
| A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma ARRY-520, KSP(Eg5) inhibitor; intravenous, Bortezomib, proteasome inhibitor; intravenous or subcutaneous, Dexamethasone, steroid; oral - Multiple Myeloma, Plasma Cell Leukemia | Phase 1 | Completed | Array Biopharma, now a wholly owned subsidiary of Pfizer | 55 | 2010-12-01 | 2020-09-30 |
Leukemia, Plasma Cell (2) · Multiple Myeloma (2) · Bites and Stings (1) · Paraproteinemias (1) · Plasmacytoma (1)
Blood Protein Disorders (2) · Cardiovascular Diseases (2) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Hemorrhagic Disorders (2) · Hemostatic Disorders (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Leukemia (2) · Lymphoproliferative Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms, Plasma Cell (2) · Vascular Diseases (2) · Chemically-Induced Disorders (1)
Bortezomib (1) · Dexamethasone (1) · Filgrastim (1) · Granulocyte Colony-Stimulating Factor (1) · Injections, Subcutaneous (1) · Proteasome Inhibitors (1) · Steroids (1) · filanesib (1)
Array Biopharma, now a wholly owned subsidiary of Pfizer (1) · Institute of Hematology & Blood Diseases Hospital, China (1)
China (1) · United States (1)